Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by Probosciseson Jan 08, 2023 11:59pm
407 Views
Post# 35210350

SEDI (System for Electronic Disclosures by Insiders)

SEDI (System for Electronic Disclosures by Insiders)SEDI (sedi.ca) is the place to go to find insider disclosures in detail.  Access public filings and then select "View Summary Reports". You can input the name of the insider, the period of the insider transactions, and select for Common Shares and Options and you will get details of every insider transaction.  It's painstaking, but you can input the name of everyone in ONC management and every member of the BOD and you will find precice transaction detail for every one of them.

Of management you will learn:
1. Matt Coffey has 96,333 common shares and 1,354,631 options
2. Kirk Look has 45,028 common shares and 815,262 options
3. Thomas Heineman has 11,000 commonshares and 425,000 options
4. Andrew de Guttadauro has 10,315 common shares and 563,157 options
5. Allison Hagerman has 4,200 common shares and 507,683 options

Of the Board of Directors you will learn:
1. Wayne Pisano has 189,941 common shares and 83,420 options
2. Deborah Brown has 48,948 common shares and 65,263 options
3. Bernd Seizinger has 314,863 common shares and 65,263 options
4. Angela Holtham has 124,238 common shares and 65,263 options
5. James Parsons has 45,000 options
6. Jonathan Rigby has 45,000 options

What is clear is that all the members of management and the BOD have a great deal to gain from a decent buyout price or partnership deal.  
<< Previous
Bullboard Posts
Next >>